These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 23429964)

  • 1. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
    Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
    Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
    Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
    Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.
    De Boeck K; Haarman E; Hull J; Lands LC; Moeller A; Munck A; Riethmüller J; Tiddens H; Volpi S; Leadbetter J; Charlton B; Malfroot A;
    J Cyst Fibros; 2017 May; 16(3):380-387. PubMed ID: 28258928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled mannitol improves lung function in cystic fibrosis.
    Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PTP; LeSouëf PN; Shadbolt B; Anderson SD; Charlton B
    Chest; 2008 Jun; 133(6):1388-1396. PubMed ID: 18339790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
    Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
    Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum.
    Daviskas E; Anderson SD; Gomes K; Briffa P; Cochrane B; Chan HK; Young IH; Rubin BK
    Respirology; 2005 Jan; 10(1):46-56. PubMed ID: 15691238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
    Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inhaled dry powder mannitol on mucus and its clearance.
    Daviskas E; Rubin BK
    Expert Rev Respir Med; 2013 Feb; 7(1):65-75. PubMed ID: 23362816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.
    Paredes Aller S; Quittner AL; Salathe MA; Schmid A
    Expert Rev Respir Med; 2018 Sep; 12(9):769-782. PubMed ID: 30025482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.
    Laska IF; Crichton ML; Shoemark A; Chalmers JD
    Lancet Respir Med; 2019 Oct; 7(10):855-869. PubMed ID: 31405826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium cromoglycate and eformoterol attenuate sensitivity and reactivity to inhaled mannitol in subjects with bronchiectasis.
    Briffa PJ; Anderson SD; Burton DL; Young IH
    Respirology; 2011 Jan; 16(1):161-6. PubMed ID: 21054671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
    Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG
    Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol.
    Scherr A; Schafroth Török S; Jochmann A; Miedinger D; Maier S; Taegtmeyer AB; Chhajed PN; Tamm M; Leuppi JD
    Chest; 2012 Oct; 142(4):919-926. PubMed ID: 22459771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.
    Teper A; Jaques A; Charlton B
    J Cyst Fibros; 2011 Jan; 10(1):1-8. PubMed ID: 20888307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled hyperosmolar agents for bronchiectasis.
    Hart A; Sugumar K; Milan SJ; Fowler SJ; Crossingham I
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD002996. PubMed ID: 24817558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.
    Flume PA; Amelina E; Daines CL; Charlton B; Leadbetter J; Guasconi A; Aitken ML
    J Cyst Fibros; 2021 Nov; 20(6):1003-1009. PubMed ID: 33715994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.
    Bilton D; Robinson P; Cooper P; Gallagher CG; Kolbe J; Fox H; Jaques A; Charlton B;
    Eur Respir J; 2011 Nov; 38(5):1071-80. PubMed ID: 21478216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis.
    Daviskas E; Anderson SD; Jaques A; Charlton B
    Chest; 2010 Apr; 137(4):861-8. PubMed ID: 19880909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.